Interferon gamma for idiopathic pulmonary fibrosis

The Lancet

Volumn 374, Issue 9685, 2009, Pages 180-182

  Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA1B INTERFERON; PLACEBO;

ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FIBROSING ALVEOLITIS; HUMAN; LUNG BIOPSY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 67650355436     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60689-9     Document Type: Note

References (14)

1. King Jr. T.E., Albera C., Bradford W.Z., et al., for the INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 10.1016/S0140-6736(09)60551-1 published online June 30.
2. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2000) 646-664
3. American Thoracic Society, and European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002) 277-304
4. Martinez F.J., Safrin S., Weycker D., et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (2005) 963-967
5. Collard H.R., Moore B.B., Flaherty K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007) 636-643
6. Wilson M.S., and Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2 (2009) 103-121
7. Vassilakis D.A., Sourvinos G., Spandidos D.A., Siafakas N.M., and Bouros D. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 162 (2000) 1115-1119
8. Kotsianidis I., Nakou E., Bouchliou I., et al. Global impairment of CD4+CD25+FOXP3+ T regulatory cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179 (2009) 1121-1130
9. Bouros D., and Antoniou K.M. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 26 (2005) 693-702
10. Antoniou K.M., Ferdoutsis E., and Bouros D. Interferons and their application in the diseases of the lung. Chest 123 (2003) 209-216
11. Vlachoyiannopoulos P.G., Tsifetaki N., Dimitriou I., Galaris D., Papiris S.A., and Moutsopoulos H.M. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis 55 (1996) 761-768
12. Ziesche R., Hofbauer E., Wittmann K., et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 (1999) 1264-1269
13. Raghu G., Brown K.K., Bradford W.Z., et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2004) 125-133
14. Antoniou K.M., Nicholson A.G., Dimadi M., et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 28 (2006) 496-504